This filing confirms deal close, SLNO no longer trades. For arbitrageurs: the narrow remaining spread (holders who did not tender get the same $53.00 through the merger) should collapse to zero. No further trading action is possible in SLNO common. Watch for the Form 15 deregistration to complete, after which all reporting obligations cease.
How the stock moved after the report
BULLISH VIEWSTOCK AT ENTRY AT T+1- T+0 · May 18 $53.01entry
- T+1 · 6mo ago 0.00%α +0.65% · $53.01
- T+5 · due 6mo ago Pending
- T+20 · due 5mo ago Pending
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, paying $53.00 per share in cash. The tender offer closed with 46,356,114 shares (88.9% of outstanding) tendered, followed by a short-form merger under Section 251(h) of the DGCL. SLNO common stock has been delisted from Nasdaq and the company will deregister its securities. This filing confirms the deal has closed, existing SLNO shareholders who did not tender in the offer will receive $53.00 per share in the merger.
Key Facts
- Acquisition by Neurocrine Biosciences at $53.00 per share in cash
- 88.9% of shares tendered in the offer (46,356,114 shares)
- Tender offer expired May 15, 2026; merger completed May 18, 2026
- SLNO common stock delisted from Nasdaq; Form 25 and Form 15 filings initiated
- All options, RSUs, and warrants cashed out in connection with the merger
- Loan and Security Agreement with Oxford Finance LLC terminated
- Entire board and all C-suite officers resigned; replaced by Neurocrine designees
- Certificate of incorporation and bylaws amended and restated
Financial Impact
Total equity value of approximately $2.9 billion based on $53.00 per share
Risk Factors
- No remaining upside for SLNO shareholders, fixed cash consideration of $53.00 per share
- Delisting and deregistration eliminate any further trading or reporting
- Appraisal rights available for shareholders who properly perfected demands, but no indication of litigation challenging the price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (SLNO), Batch item 1 | 0001193125-26-228016 |
| Document: d143266d8k.htm | 0001354457-26-000469 |
| Document: d143266dex31.htm | 0001193125-26-228016 |
| Document: 0001193125-26-228016-index-headers.html | 0001193125-26-228016 |
| Document: 0001193125-26-228016-index.html | 0001193125-26-228016 |
| Document: 0001193125-26-228016.txt | 0001193125-26-228016 |
| 25-NSE Filing (SLNO), Batch item 7 | 0001354457-26-000469 |
Track record
10 reports on SLNO
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +2.57% at T+1 after the Feb 26, 2026 report. 2 of 3 went positive at some point.
Filters
- Jun 11, 202622w ago Institutional Cluster Bullish 6/10 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 No price data
- May 28, 202624w ago 15-12G Bearish 8/10 No price data
- May 28, 202624w ago EFFECT Bearish 5/10 No price data
- May 18, 202626w ago 8-K / 25-NSE Bullish 8/10 Viewing Entry $53.01 No price data
- Apr 7, 202631w ago 8-K Bearish 7/10 Entry $52.35 to $52.62 ▼ −0.52% +4.81% vs SPY
- Apr 6, 202632w ago 8-K Bullish 8/10 Entry $52.25 to $52.64 ▲ +0.75% −3.39% vs SPY
- Mar 27, 202633w ago Insider Cluster Neutral 3/10 Entry $30.05 to $52.25 ▲ +73.88% +70.01% vs SPY
- Feb 26, 202637w ago 8-K Bullish 8/10 Entry $38.09 to $38.57 ▲ +1.26% +2.42% vs SPY
- Feb 26, 202637w ago 8-K Neutral 3/10 Entry $38.09 to $38.57 ▲ +1.26% +2.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers